130results about How to "Prevention and treatment" patented technology

Compositions which provide slowly digestible starch and a source of fermentable dietary fiber. Microparticles in which starch is entrapped in a crosslinked matrix to provide dietary benefit. Such microparticles are used to deliver glucose to targeted regions in the small intestine for beneficial physiological effects, and fermentable dietary fiber to the colon to improve colon health and to treat diseases of the colon. Microparticles can be employed to selectively deliver fermentable dietary fiber to targeted portions of the colon. A method for making the microparticles is provided as well as methods for using the microparticles for controlled digestion of starch on ingestion in the small intestine and methods for using the microparticles to deliver dietary fiber. The microparticles with entrapped starch provide a low glycemic index and extended glucose release in food products and food ingredients. The microparticles with entrapped starch can, in particular, be used as an ingredient in foods that are to be cooked.

Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

It is intended to provide preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis. The above object can be achieved by preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis characterized by containing a specific compound having a CCR (CC chemokine receptor) antagonism.

Non-steroidal anti-infammatory after shave preparations to aid in the prevention and treatment of Pseudofolliculitis Barbae and a method of delivering the ingredients of the preparation to affected areas of the skin. Formula I comprises ethanol, salicylic acid, propylene glycol, glycerine, fragrance, at least one compound for reducing skin irritation and at least one non-steroidal anti-inflammatory agent wherein said non-steroidal anti-inflammatory agent is an NSAID drug, a naturally occurring herbal compound containing an anti-inflammatory component or combinations thereof. Formula 11 comprises water, hydrolyzed oat flour, sorbitol, methylparaben, petrolatum, lanolin, cetyl alcohol, sunflower seed oil, stearic acid, propylparaben, triethanoloamine, a preservative, and at least one non-steroidal anti-inflammatory agent wherein said non-steroidal anti-inflammatory agent is an NSAID drug, a naturally occurring herbal compound containing an anti-inflammatory component or combinations thereof. The formulas have sufficient viscosity to allow the after shave preparation to remain on an affected area of the skin for a sufficient period of time to optimize the skin irritation reduction and anti inflammatory effects on the affected area thus providing local relief from irritation due to PFB.

An object is to provide a method for determining the risk of arteriosclerotic disease which can accurately determine the tendency to develop an arteriosclerotic disease or tendency for advance thereof as the risk of arteriosclerotic disease and can be utilized in prevention and treatment of arteriosclerosis and to provide, for example, a kit for analyzing genetic polymorphism and apparatus for determining the risk of arteriosclerotic disease for use in determination of the risk. A method for determining the risk of arteriosclerotic disease includes a risk evaluation process for evaluating the risk of arteriosclerosis caused by genetic polymorphisms, based on the risk of arteriosclerosis inherent to a combination of plural genetic polymorphisms, from the genotype of a subject on the genetic polymorphisms, in which the combination of plural genetic polymorphisms includes at least one combination of genetic polymorphisms having a significant positive correlation with the carotid arterial intima-media thickness.

The present invention relates to certain polyhydroxylated pentacyclic triterpene acids of formula (I) for use as HMG-CoA reductase inhibitors in the prophylactic and/or therapeutic treatment of a disease, disorder or condition that responds to a reduction of the HMG-CoA reductase activity in a mammal, preferably a human being. The present invention further relates to certain mixtures and plant extracts comprising euscaphic acid and tormentic acid, wherein the amount of euscaphic acid to tormentic acid exceeds a certain ratio. Further, the present invention also relates to a formulation, preferably pharmaceutical or nutraceutical formulation, comprising one or more of said compounds of formula (I), a composition according to the present invention or a plant extract according to the present invention. Also, the present invention relates to a process for obtaining certain polyhydroxylated pentacyclic triterpene acids of formula (I), a composition according to the present invention or a plant extract according to the present invention.

The present invention is directed to a food composition including an edible base mix component and a dried probiotic component which that may be stored at room temperature and converted to a frozen dessert with minimal effects to the viability of probiotics. Accordingly, a consumer ingesting the frozen dessert is provided with a beneficial amount of viable probiotics. Also provided herein are one or more methods for manufacturing the food compositions and using the subject food composition in frozen dessert products.

The invention relates to the field of traditional Chinese medicines, especially relates to a traditional Chinese medicine composition, and application and preparation method thereof, cold tea and a preparation method thereof, a medicinal preparation and a cosmetic. The traditional Chinese medicine composition is prepared from, in parts by weight, 9-18 parts of flos lonicerae, 2-8 parts of flos chrysanthemi, 1-5 parts of radix glycyrrhizae, 1-5 parts of herba lophatheri, 1-5 parts of herba menthae, 1-5 parts of spica prunellae, 1-5 parts of fructus lycii, 1-5 parts of fructus momordicae, and other raw materials. The traditional Chinese medicine composition possesses the efficacy of enhancing immunity and treating wind-heat cold, also possesses effects of resisting oxidation and maintaining beauty, has certain auxiliary treatment effect on diabetes, melancholia, hypertension, bronchitis and the like, also is capable of effectively treating excessive internal heat, heatstroke and constipation, contains heat, protein, carbohydrates, sodium and multiple elements, and other nutrients beneficial to human body, has the color, taste and other physical and chemical and hygienic indexes according to national standard requirements, and is extremely light in original unpleasant taste, sweet in taste and good in mouthfeel.

[Object] To provide a pharmaceutical product (chemotherapeutic agent) effective in the prevention and treatment of hyperlipidemia, obesity, etc.

[Solving Means] A phenylimidazole compound represented by the following General Formula (1):

This invention relates to a method of inhibiting OPN production, which comprises administering an effective amount of a pyridazine derivative represented by the following formula (I) or a salt thereof:

wherein:

• • R¹ means a substituted or unsubstituted phenyl or pyridyl group;
  • R² means a substituted phenyl group;
  • R³ means a hydrogen atom or a substituted or unsubstituted phenyl or pyridyl group;
  • A means a single bond, a C_1-6 linear or branched alkylene group, or a C_2-9 linear or branched alkenylene group; and X means an oxygen atom or a sulfur atom.

The present invention relates to use of ginsenoside Rg3, Rg5 or Rk1, or extract of ginseng, red ginseng or processed ginseng comprising the ginsenosides; a composition for preventing or treating angiostenosis and restenosis comprising the ginsenosides or extracts; a method for preventing or treating angiostenosis and restenosis by administrating the ginsenosides or extracts comprising the ginsenosides; and a preparation method of agents for preventing or treating angiostenosis and restenosis. The present composition can effectively prevent or treat angiostenosis and restenosis.

The present invention relates to a liquid pharmaceutical composition containing an N-phenylpyrazole derivative as active ingredient and alpha-(tetrahydrofuranyl)-omega-hydroxypoly(oxy-1,2-ethanediyl) as solvent for the treatment and/or prevention of infestations with fleas in domestic animals.